- Cybin-sponsored study will use Kernel Flow, Kernel’s quantitative neuroimaging.
- Company hopes to learn more about impact ketamine has on brain activity, overall mental well-being.
- Study results may lead to future studies supporting CYBN’s mission to develop psychedelics into therapeutics.
Cybin’s (NEO: CYBN) (NYSE American: CYBN) efforts to transform the mental-health treatment landscape have reached a key milestone: the company is actively recruiting participants for its upcoming feasibility study using Kernel Flow, Kernel’s quantitative neuroimaging technology (https://ibn.fm/9aSxc).
“The feasibility study using Kernel Flow offers an opportunity for researchers and our study participants to quantifiably gather information on a psychedelic experience,” said Cybin CEO Doug Drysdale. “Until now, our understanding of the psychedelic experience has been fairly subjective. This study may lead to larger studies that have the potential to bridge the gap between bringing psychedelics to therapeutics as we learn more about the advantages of these important molecules on brain activity and overall mental well-being.”
Cybin, a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), received U.S. Food and Drug Administration Investigational New Drug authorization last year and Institutional Review Board approval earlier this year for the study, which is designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics (https://ibn.fm/WISGk).
During the study, participants will wear the Kernel Flow headset while receiving either a low dose of ketamine or a placebo. The Kernel Flow device, which features hi-tech sensors to record brain activity, will monitor the participants before, during and after receiving the substances. Additional information will be obtained from structured questionnaires and validated assessments that will be gathered from the participants during study visits and a follow-up.
“By leveraging the Kernel Flow technology, we may have the ability to measure longitudinal brain activity before, during and after a psychedelic experience, and collect quantitative data as opposed to subjective patient reporting,” said Drysdale. “We believe the results of this study will lead to future studies that will test the effectiveness of psychedelic treatments and will further support our mission to develop psychedelics into therapeutics.”
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland. The company is focused on progressing psychedelics to therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment